Navigation Links
Two New Jersey Hormone Therapy Lawsuits Dismissed
Date:7/14/2008

MADISON, N.J., July 14 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) announced today that Judge Jamie D. Happas of the New Jersey Superior Court in New Brunswick has granted Wyeth's motion for summary judgment in two hormone therapy cases that were scheduled for trial later this year. The court dismissed the cases of Bailey v. Wyeth, which was to have begun on September 15, and DeBoard v. Wyeth, which had an October 27 trial date. The plaintiffs in both cases alleged they developed breast cancer as a result of the use of Prempro(TM) and Premarin(R), hormone therapy products marketed by Wyeth, as well as Provera(R), a progestin product marketed by Upjohn.

In granting the motions, Judge Happas ruled, among other things, that the plaintiffs "failed to provide the specific type of evidence necessary to overcome the presumption of adequacy afforded [to] FDA-approved labeling" by New Jersey law and that the warnings were "adequate as a matter of law."

"We believe the court's ruling was a proper application of New Jersey law and is consistent with a growing body of law around the nation, rejecting challenges to FDA-approved labeling," says Lauren E. Handler, a partner with Porzio Bromberg & Newman, P.C., a New Jersey-based firm representing Wyeth in both cases.

About Wyeth

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.


'/>"/>
SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. World Chemical Industry Has Decided to Gather at ChemOutsourcing Show on September 7-9 in New Jersey
2. 60 Specialty Chemical, Fine Chemical & Custom Synthesis Providers Will Exhibit at Pharma ChemOutsourcing on September 8-9 in New Jersey
3. E. coli Outbreak in New Jersey?
4. API and Raw Material Supply Concerns Focal Point of Pharma ChemOutsourcing Conference September 8-9 in New Jersey
5. Chemistry Outsourcing Conference Unveils 90-Speaker Conference Program to Take Place September 8-9 in New Jersey
6. StemCyte Locates East Coast Operations in New Jersey
7. BioSpace to Host Regeneron Pharmaceuticals Career Fair in Whippany, New Jersey
8. Novo Nordisk Expands U.S. Headquarters in New Jersey
9. BioSpace New Jersey Career Fair Attracts Over 1,000 Bioscience Candidates
10. NicOx Opens U.S. Headquarters in New Jersey
11. Secure Symbology: Making New Jersey Proud While Saving Lives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... -- International research firm Parks Associates announced today that ... TMA 2017 Annual Meeting , October 11 in Scottsdale, Arizona ... market and how smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase ... "The residential security market has experienced continued growth, ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings announced ... by which its ProCell stem cell therapy prevents ... ischemia.  The Company, demonstrated that treatment with ProCell ... limbs saved as compared to standard bone marrow ... HGF resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... (PRWEB) , ... October 09, ... ... published on October 5, 2017, in the medical journal, Epilepsia, Brain Sentinel’s ... the gold standard, video EEG, in detecting generalized tonic-clonic seizures (GTCS) using ...
(Date:10/6/2017)... (PRWEB) , ... October 06, 2017 , ... ... entrepreneurship within the healthcare and technology sector at their fourth annual Conference where ... featuring 30 inspiring speakers and the ELEVATE pitch competition showcasing early stage digital ...
Breaking Biology Technology:
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
(Date:3/29/2017)... , March 29, 2017  higi, the health ... in North America , today announced ... and the acquisition of EveryMove. The new investment and ... set of tools to transform population health activities through ... lifestyle data. higi collects and secures data ...
Breaking Biology News(10 mins):